CAI Q2 2025 Earnings — Caris Life Sciences, Inc. Revenue & Financial Results | Market Cap Arena

CAICaris Life Sciences, Inc.

$5B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$181M+81.3% YoY

Gross Profit

$114M62.7% margin

Operating Income

$18M9.9% margin

Net Income

-$72M-39.6% margin

EPS (Diluted)

$-1.87

QoQ Revenue Growth

+50.0%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$6M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$955M

Total Liabilities

$502M

Stockholders' Equity

$453M

Cash & Equivalents

$719M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$181M	$100M	+81.3%
Gross Profit	$114M	$38M	+202.7%
Operating Income	$18M	$67M	-73.2%
Net Income	-$72M	-$66M	-8.5%

Revenue Segments

Pharma Research And Development Services

$18M100%

Geographic Segments

UNITED STATES

$178M98%

Non-US

$3M2%